BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27418643)

  • 21. Early Progressing Follicular Lymphoma.
    Wallace D; Casulo C
    Curr Oncol Rep; 2021 Nov; 23(12):149. PubMed ID: 34797453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
    Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
    Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.
    Boughan KM; Caimi PF
    Curr Oncol Rep; 2019 May; 21(7):63. PubMed ID: 31119485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
    Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
    Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
    Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
    J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
    Fernández-Miranda I; Pedrosa L; Llanos M; Franco FF; Gómez S; Martín-Acosta P; García-Arroyo FR; Gumá J; Horcajo B; Ballesteros AK; Gálvez L; Martínez N; Marín M; Sequero S; Navarro M; Yanguas-Casás N; Calvo V; Rueda-Domínguez A; Provencio M; Sánchez-Beato M
    Clin Cancer Res; 2023 Jan; 29(1):209-220. PubMed ID: 36269794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
    Formica V; Norman AR; Cunningham D; Wotherspoon A; Oates J; Chong G
    Acta Haematol; 2009; 122(4):193-9. PubMed ID: 19887775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
    Gao F; Liu H; Meng X; Liu J; Wang J; Yu J; Liu X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Golchehre Z; Chavoshzadeh Z; He J; Zhang H; Wang X
    Br J Haematol; 2023 Sep; 202(6):1151-1164. PubMed ID: 37455019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma.
    Hu J; Gao F; Zhao J; Song W; Wang Y; Zheng Y; Wang L; Han W; Ma L; Wang J; Bai M; Guan T; Xi Y; Zhang H; Qiu L; Su L
    Front Oncol; 2023; 13():1090610. PubMed ID: 37427106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
    Epperla N; Welkie RL; Torka P; Shouse G; Karmali R; Shea L; Anampa-Guzmán A; Oh TS; Reaves H; Tavakkoli M; Lindsey K; Greenwell IB; Hansinger E; Thomas C; Chowdhury SM; Annunzio K; Christian B; Barta SK; Geethakumari PR; Bartlett NL; Herrera AF; Grover NS; Olszewski AJ
    J Hematol Oncol; 2023 May; 16(1):49. PubMed ID: 37158890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
    Bachy E; Maurer MJ; Habermann TM; Gelas-Dore B; Maucort-Boulch D; Estell JA; Van den Neste E; Bouabdallah R; Gyan E; Feldman AL; Bargay J; Delmer A; Slager SL; Gomes da Silva M; Fitoussi O; Belada D; Maisonneuve H; Intragumtornchai T; Ansell SM; Lamy T; Dartigues P; Link BK; Seymour JF; Cerhan JR; Salles G
    Blood; 2018 Jul; 132(1):49-58. PubMed ID: 29666118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.
    Rajamaki A; Sorigue M; Prusila REI; Kuusisto MEL; Kuitunen H; Jantunen E; Mercadal S; Turpeenniemi-Hujanen T; Sancho JM; Sunela K; Kuittinen O
    Acta Oncol; 2024 May; 63():267-272. PubMed ID: 38709114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models.
    Li Y; Zhang Y; Wang W; Wei C; Zhao D; Zhang W
    Cancer Manag Res; 2022; 14():1385-1393. PubMed ID: 35422658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression.
    Montoto S; López-Guillermo A; Altés A; Perea G; Ferrer A; Camós M; Villela L; Bosch F; Esteve J; Cervantes F; Bladé J; Nomdedeu B; Campo E; Sierra J; Montserrat E
    Ann Oncol; 2004 Oct; 15(10):1484-9. PubMed ID: 15367408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
    Sarkozy C; Trneny M; Xerri L; Wickham N; Feugier P; Leppa S; Brice P; Soubeyran P; Gomes Da Silva M; Mounier C; Offner F; Dupuis J; Caballero D; Canioni D; Paula M; Delarue R; Zachee P; Seymour J; Salles G; Tilly H
    J Clin Oncol; 2016 Aug; 34(22):2575-82. PubMed ID: 27298402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months.
    Yoon SE; Cho J; Kim WS; Kim SJ
    J Cancer; 2021; 12(9):2488-2497. PubMed ID: 33854610
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.